Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06452706 |
| Consolidated Lead Sponsor | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 42 participants (ESTIMATED) |
| Registered Start Date | 2024-11-14 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Harbin Medical University Cancer Hospital | Harbin, China | Open Hospital Dossier -> |
| Zhongnan Hospital of Wuhan University | Wuhan, China | Open Hospital Dossier -> |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, China | Open Hospital Dossier -> |
| The First Affiliated Hospital of Xi 'an Jiaotong University | Xi'an, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.